Sign in Subscribe
Cancer

HER2+ Gastric Cancer Pipeline: Insights into Key Players, Emerging Therapies, and Treatment Landscape

Strategic Insights

— 2 min read

The HER2-positive gastric cancer pipeline is a rapidly evolving space with over 20 companies and 20 pipeline drugs in various stages of development. DelveInsight's report "HER2 Positive Gastric Cancer - Pipeline Insight, 2025" provides a comprehensive analysis of the pipeline therapies, highlighting the promising emerging drugs, key companies, and the current treatment algorithm.

The report emphasizes the need for more effective and targeted therapies for HER2-positive gastric cancer, which contributes significantly to global cancer morbidity and mortality. The pipeline therapies, including SHR-A1811, Cinrebafusp alfa, and BI-1607, are being developed by key players such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, and BioInvent International.

The HER2-positive gastric cancer treatment landscape is characterized by a subset of patients who overexpress the HER2 protein, leading to rapid tumor growth. Advances in targeted therapies, such as HER2 inhibitors, have provided promising approaches for managing HER2-positive gastric cancers. The report highlights the current treatment patterns and the therapeutic assessment of pipeline drugs by route of administration, molecule type, and product type.

Key Takeaways:

  • DelveInsight's HER2+ Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2+ Gastric Cancer treatment.
  • In July 2024, Merck & Co. announced that the Phase III KEYNOTE-811 trial achieved its dual primary endpoint of overall survival.
  • In April 2024, ENHERTU (fam-trastuzumab deruxtecan-nxki) received approval in the US as the first tumor-agnostic HER2-targeted therapy for patients with metastatic HER2-positive solid tumors who have undergone prior treatment.
  • Key companies in the HER2+ Gastric Cancer treatment landscape include Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, and others.
  • Promising HER2+ Gastric Cancer pipeline therapies in various stages of development include SHR-A1811, Cinrebafusp alfa, BI-1607, and others.
  • Over 20 key companies are actively developing therapies for HER2-positive gastric cancer, with Jiangsu HengRui Medicine Co., Ltd. having drug candidates in the most advanced stage of development.
  • The HER2+ Gastric Cancer pipeline report provides the therapeutic assessment of pipeline drugs by the Route of Administration, categorizing products as Intravenous, Subcutaneous, Oral, and Intramuscular.
  • The report highlights the need for more effective and targeted therapies for HER2-positive gastric cancer, which contributes significantly to global cancer morbidity and mortality.

Statistics:

  • 20+ companies and 20+ pipeline drugs are in various stages of development for HER2+ Gastric Cancer treatment.
  • Over 20 key companies are actively developing therapies for HER2-positive gastric cancer.
  • SHR-A1811, Cinrebafusp alfa, and BI-1607 are among the promising emerging drugs in the pipeline.
  • Jiangsu HengRui Medicine Co., Ltd. has drug candidates in the most advanced stage of development, specifically Phase III clinical trials.
  • ENHERTU (fam-trastuzumab deruxtecan-nxki) received approval in the US as the first tumor-agnostic HER2-targeted therapy for patients with metastatic HER2-positive solid tumors who have undergone prior treatment.

Sources:

  • DelveInsight's "HER2 Positive Gastric Cancer - Pipeline Insight, 2025" report
  • M2 PressWIRE-June 24, 2025
  • DelveInsight's website
  • www.abnewswire.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.co.uk on the world wide web. Inquiries to info@m2.co.uk)).

Read more